Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Go online to PeerView.com/NGF860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you prepared for new standards of care in HCC
management—and the implications for optimized, sequential
treatment? Find out by viewing this educational activity, based on
a recent PeerView Live event, where our experts will demonstrate
how to develop a highly personalized management model in HCC that
exploits potent new immunotherapy combinations, modern TKI therapy,
and newer treatment modalities. Throughout, our experts will
provide “Tumor Board”-style illustrations of how to address the
needs of a given patient, implement appropriate therapeutic
sequencing, and embrace the increasingly important role of
multidisciplinary care across the disease continuum. Upon
completion of this activity, participants should be better able to:
Assess the efficacy/safety profiles and clinical roles of new and
novel systemic therapy options and combinations for patients with
advanced HCC, Implement a tailored approach to treatment selection
and sequencing for patients with HCC, taking into consideration
recent clinical evidence, expert and guideline recommendations, and
patient-, disease-, and treatment-specific factors, Consider
ongoing clinical trials assessing innovative strategies, including
tumor treating fields, combinations of locoregional therapies with
systemic therapies and adjuvant immunotherapies, as treatment
options for patients with HCC across different disease and
treatment settings, Integrate multidisciplinary care approaches,
including strategies to maximize treatment efficacy, safety,
tolerability, and patient QOL, for the optimal assessment and
management of patients with HCC across the disease continuum.